#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-7	Imaging	_
1-2	8-18	resilience	_
1-3	19-22	and	_
1-4	23-31	recovery	_
1-5	32-34	in	_
1-6	35-42	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-7	43-53	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-8	54-64	Background	_
1-9	65-68	and	_
1-10	69-73	aims	_
1-11	74-84	Resilience	_
1-12	85-88	and	_
1-13	89-97	recovery	_
1-14	98-101	are	_
1-15	102-104	of	_
1-16	105-115	increasing	_
1-17	116-126	importance	_
1-18	127-129	in	_
1-19	130-133	the	_
1-20	134-139	field	_
1-21	140-142	of	_
1-22	143-150	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-23	151-161	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-24	162-163	(	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-25	164-166	AD	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-26	167-168	)	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-27	169-170	.	_

2-1	171-175	This	_
2-2	176-181	paper	_
2-3	182-191	describes	_
2-4	192-195	how	_
2-5	196-203	imaging	_
2-6	204-211	studies	_
2-7	212-214	in	_
2-8	215-218	man	_
2-9	219-222	can	_
2-10	223-225	be	_
2-11	226-230	used	_
2-12	231-233	to	_
2-13	234-240	assess	_
2-14	241-244	the	_
2-15	245-260	neurobiological	_
2-16	261-271	correlates	_
2-17	272-274	of	_
2-18	275-285	resilience	_
2-19	286-289	and	_
2-20	290-291	,	_
2-21	292-294	if	_
2-22	295-307	longitudinal	_
2-23	308-309	,	_
2-24	310-312	of	_
2-25	313-320	disease	_
2-26	321-333	trajectories	_
2-27	334-335	,	_
2-28	336-347	progression	_
2-29	348-353	rates	_
2-30	354-357	and	_
2-31	358-365	markers	_
2-32	366-369	for	_
2-33	370-378	recovery	_
2-34	379-381	to	_
2-35	382-388	inform	_
2-36	389-398	treatment	_
2-37	399-402	and	_
2-38	403-413	prevention	_
2-39	414-421	options	_
2-40	422-423	.	_

3-1	424-431	Methods	_
3-2	432-440	Original	_
3-3	441-449	articles	_
3-4	450-452	on	_
3-5	453-461	recovery	_
3-6	462-465	and	_
3-7	466-476	resilience	_
3-8	477-479	in	_
3-9	480-487	alcohol	_
3-10	488-497	addiction	_
3-11	498-501	and	_
3-12	502-505	its	_
3-13	506-521	neurobiological	_
3-14	522-532	correlates	_
3-15	533-537	were	_
3-16	538-548	identified	_
3-17	549-553	from	_
3-18	554-555	‘	_
3-19	556-562	PubMed	_
3-20	563-564	’	_
3-21	565-568	and	_
3-22	569-573	have	_
3-23	574-578	been	_
3-24	579-587	analyzed	_
3-25	588-591	and	_
3-26	592-601	condensed	_
3-27	602-608	within	_
3-28	609-610	a	_
3-29	611-621	systematic	_
3-30	622-632	literature	_
3-31	633-639	review	_
3-32	640-641	.	_

4-1	642-649	Results	_
4-2	650-658	Findings	_
4-3	659-667	deriving	_
4-4	668-672	from	_
4-5	673-674	(	_
4-6	675-676	f	_
4-7	677-678	)	_
4-8	679-682	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
4-9	683-686	and	_
4-10	687-690	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
4-11	691-698	studies	_
4-12	699-703	have	_
4-13	704-714	identified	_
4-14	715-720	links	_
4-15	721-728	between	_
4-16	729-738	increased	_
4-17	739-749	resilience	_
4-18	750-753	and	_
4-19	754-758	less	_
4-20	759-772	task-elicited	_
4-21	773-779	neural	_
4-22	780-790	activation	_
4-23	791-797	within	_
4-24	798-801	the	_
4-25	802-807	basal	_
4-26	808-815	ganglia	_
4-27	816-817	,	_
4-28	818-821	and	_
4-29	822-830	benefits	_
4-30	831-833	of	_
4-31	834-844	heightened	_
4-32	845-851	neural	_
4-33	852-862	prefrontal	_
4-34	863-869	cortex	_
4-35	870-871	(	_
4-36	872-875	PFC	_
4-37	876-877	)	_
4-38	878-888	engagement	_
4-39	889-898	regarding	_
4-40	899-909	resilience	_
4-41	910-912	in	_
4-42	913-914	a	_
4-43	915-922	broader	_
4-44	923-928	sense	_
4-45	929-930	,	_
4-46	931-937	namely	_
4-47	938-948	resilience	_
4-48	949-956	against	_
4-49	957-964	relapse	_
4-50	965-967	in	_
4-51	968-973	early	_
4-52	974-984	abstinence	_
4-53	985-987	of	_
4-54	988-990	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-55	991-992	.	_

5-1	993-1004	Furthermore	_
5-2	1005-1006	,	_
5-3	1007-1015	findings	_
5-4	1016-1028	consistently	_
5-5	1029-1036	propose	_
5-6	1037-1039	at	_
5-7	1040-1045	least	_
5-8	1046-1053	partial	_
5-9	1054-1062	recovery	_
5-10	1063-1065	of	_
5-11	1066-1071	brain	_
5-12	1072-1079	glucose	_
5-13	1080-1090	metabolism	_
5-14	1091-1094	and	_
5-15	1095-1104	executive	_
5-16	1105-1108	and	_
5-17	1109-1116	general	_
5-18	1117-1126	cognitive	_
5-19	1127-1138	functioning	_
5-20	1139-1140	,	_
5-21	1141-1143	as	_
5-22	1144-1148	well	_
5-23	1149-1151	as	_
5-24	1152-1162	structural	_
5-25	1163-1173	plasticity	_
5-26	1174-1181	effects	_
5-27	1182-1192	throughout	_
5-28	1193-1196	the	_
5-29	1197-1202	brain	_
5-30	1203-1205	of	_
5-31	1206-1223	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
5-32	1224-1232	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
5-33	1233-1239	during	_
5-34	1240-1243	the	_
5-35	1244-1250	course	_
5-36	1251-1253	of	_
5-37	1254-1259	short	_
5-38	1260-1261	,	_
5-39	1262-1268	medium	_
5-40	1269-1272	and	_
5-41	1273-1282	long-term	_
5-42	1283-1293	abstinence	_
5-43	1294-1295	,	_
5-44	1296-1300	even	_
5-45	1301-1305	when	_
5-46	1306-1314	patients	_
5-47	1315-1319	only	_
5-48	1320-1327	lowered	_
5-49	1328-1333	their	_
5-50	1334-1341	alcohol	_
5-51	1342-1353	consumption	_
5-52	1354-1356	to	_
5-53	1357-1358	a	_
5-54	1359-1367	moderate	_
5-55	1368-1373	level	_
5-56	1374-1375	.	_

6-1	1376-1388	Additionally	_
6-2	1389-1390	,	_
6-3	1391-1399	specific	_
6-4	1400-1407	factors	_
6-5	1408-1412	were	_
6-6	1413-1418	found	_
6-7	1419-1423	that	_
6-8	1424-1430	appear	_
6-9	1431-1433	to	_
6-10	1434-1443	influence	_
6-11	1444-1449	these	_
6-12	1450-1458	observed	_
6-13	1459-1464	brain	_
6-14	1465-1473	recovery	_
6-15	1474-1483	processes	_
6-16	1484-1486	in	_
6-17	1487-1489	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
6-18	1490-1491	,	_
6-19	1492-1495	e.g	_
6-20	1496-1497	.	_

7-1	1498-1516	genotype-dependent	_
7-2	1517-1525	neuronal	_
7-3	1526-1527	(	_
7-4	1528-1530	re	_
7-5	1531-1532	)	_
7-6	1533-1539	growth	_
7-7	1540-1541	,	_
7-8	1542-1557	gender-specific	_
7-9	1558-1564	neural	_
7-10	1565-1573	recovery	_
7-11	1574-1581	effects	_
7-12	1582-1583	,	_
7-13	1584-1592	critical	_
7-14	1593-1604	interfering	_
7-15	1605-1612	effects	_
7-16	1613-1615	of	_
7-17	1616-1627	psychiatric	_
7-18	1628-1641	comorbidities	_
7-19	1642-1643	,	_
7-20	1644-1654	additional	_
7-21	1655-1662	smoking	_
7-22	1663-1665	or	_
7-23	1666-1675	marijuana	_
7-24	1676-1686	influences	_
7-25	1687-1688	,	_
7-26	1689-1691	or	_
7-27	1692-1702	adolescent	_
7-28	1703-1710	alcohol	_
7-29	1711-1716	abuse	_
7-30	1717-1718	.	_

8-1	1719-1730	Conclusions	_
8-2	1731-1743	Neuroimaging	_
8-3	1744-1752	research	_
8-4	1753-1756	has	_
8-5	1757-1766	uncovered	_
8-6	1767-1782	neurobiological	_
8-7	1783-1790	markers	_
8-8	1791-1795	that	_
8-9	1796-1802	appear	_
8-10	1803-1805	to	_
8-11	1806-1808	be	_
8-12	1809-1815	linked	_
8-13	1816-1818	to	_
8-14	1819-1829	resilience	_
8-15	1830-1833	and	_
8-16	1834-1842	improved	_
8-17	1843-1851	recovery	_
8-18	1852-1862	capacities	_
8-19	1863-1867	that	_
8-20	1868-1871	are	_
8-21	1872-1883	furthermore	_
8-22	1884-1894	influenced	_
8-23	1895-1897	by	_
8-24	1898-1905	various	_
8-25	1906-1913	factors	_
8-26	1914-1918	such	_
8-27	1919-1921	as	_
8-28	1922-1928	gender	_
8-29	1929-1931	or	_
8-30	1932-1940	genetics	_
8-31	1941-1942	.	_

9-1	1943-1955	Consequently	_
9-2	1956-1957	,	_
9-3	1958-1964	future	_
9-4	1965-1980	system-oriented	_
9-5	1981-1991	approaches	_
9-6	1992-1995	may	_
9-7	1996-2000	help	_
9-8	2001-2003	to	_
9-9	2004-2013	establish	_
9-10	2014-2015	a	_
9-11	2016-2021	broad	_
9-12	2022-2040	neuroscience-based	_
9-13	2041-2049	research	_
9-14	2050-2059	framework	_
9-15	2060-2063	for	_
9-16	2064-2071	alcohol	_
9-17	2072-2082	dependence	_
9-18	2083-2084	.	_

10-1	2085-2092	Methods	_
10-2	2093-2099	Search	_
10-3	2100-2108	strategy	_
10-4	2109-2111	We	_
10-5	2112-2126	systematically	_
10-6	2127-2135	reviewed	_
10-7	2136-2139	the	_
10-8	2140-2148	existing	_
10-9	2149-2159	literature	_
10-10	2160-2162	up	_
10-11	2163-2165	to	_
10-12	2166-2174	November	_
10-13	2175-2179	2017	_
10-14	2180-2185	using	_
10-15	2186-2192	PUBMED	_
10-16	2193-2203	electronic	_
10-17	2204-2212	database	_
10-18	2213-2216	for	_
10-19	2217-2220	the	_
10-20	2221-2235	identification	_
10-21	2236-2238	of	_
10-22	2239-2251	neuroimaging	_
10-23	2252-2259	studies	_
10-24	2260-2273	investigating	_
10-25	2274-2282	recovery	_
10-26	2283-2289	and/or	_
10-27	2290-2300	resilience	_
10-28	2301-2303	in	_
10-29	2304-2311	alcohol	_
10-30	2312-2322	dependence	_
10-31	2323-2325	or	_
10-32	2326-2333	alcohol	_
10-33	2334-2344	dependence	_
10-34	2345-2347	in	_
10-35	2348-2354	humans	_
10-36	2355-2356	,	_
10-37	2357-2369	respectively	_
10-38	2370-2371	.	_

11-1	2372-2374	We	_
11-2	2375-2384	therefore	_
11-3	2385-2389	used	_
11-4	2390-2393	the	_
11-5	2394-2403	following	_
11-6	2404-2410	search	_
11-7	2411-2416	terms	_
11-8	2417-2418	:	_
11-9	2419-2426	imaging	_
11-10	2427-2428	,	_
11-11	2429-2441	neuroimaging	_
11-12	2442-2443	,	_
11-13	2444-2453	addiction	_
11-14	2454-2455	,	_
11-15	2456-2466	dependence	_
11-16	2467-2468	,	_
11-17	2469-2476	alcohol	_
11-18	2477-2478	*	_
11-19	2479-2480	,	_
11-20	2481-2490	substance	_
11-21	2491-2494	use	_
11-22	2495-2496	*	_
11-23	2497-2498	,	_
11-24	2499-2508	substance	_
11-25	2509-2512	use	_
11-26	2513-2521	disorder	_
11-27	2522-2523	,	_
11-28	2524-2532	recovery	_
11-29	2533-2534	,	_
11-30	2535-2545	resilience	_
11-31	2546-2547	.	_

12-1	2548-2562	Bibliographies	_
12-2	2563-2565	of	_
12-3	2566-2574	relevant	_
12-4	2575-2583	articles	_
12-5	2584-2588	were	_
12-6	2589-2601	additionally	_
12-7	2602-2610	screened	_
12-8	2611-2614	for	_
12-9	2615-2622	further	_
12-10	2623-2631	relevant	_
12-11	2632-2643	information	_
12-12	2644-2645	.	_

13-1	2646-2651	Study	_
13-2	2652-2661	selection	_
13-3	2662-2664	We	_
13-4	2665-2673	included	_
13-5	2674-2687	peer-reviewed	_
13-6	2688-2696	original	_
13-7	2697-2704	studies	_
13-8	2705-2717	irrespective	_
13-9	2718-2720	of	_
13-10	2721-2725	when	_
13-11	2726-2729	the	_
13-12	2730-2735	study	_
13-13	2736-2739	was	_
13-14	2740-2749	conducted	_
13-15	2750-2753	and	_
13-16	2754-2762	excluded	_
13-17	2763-2769	single	_
13-18	2770-2774	case	_
13-19	2775-2782	studies	_
13-20	2783-2784	,	_
13-21	2785-2792	reviews	_
13-22	2793-2796	and	_
13-23	2797-2810	meta-analyses	_
13-24	2811-2812	.	_

14-1	2813-2816	For	_
14-2	2817-2820	the	_
14-3	2821-2825	sake	_
14-4	2826-2828	of	_
14-5	2829-2838	parsimony	_
14-6	2839-2840	,	_
14-7	2841-2843	we	_
14-8	2844-2851	further	_
14-9	2852-2860	excluded	_
14-10	2861-2873	neuroimaging	_
14-11	2874-2881	studies	_
14-12	2882-2887	using	_
14-13	2888-2895	imaging	_
14-14	2896-2906	techniques	_
14-15	2907-2912	other	_
14-16	2913-2917	than	_
14-17	2918-2928	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-18	2929-2937	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-19	2938-2947	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-20	2948-2955	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-21	2956-2957	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-22	2958-2962	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-23	2963-2964	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-24	2965-2966	,	_
14-25	2967-2977	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
14-26	2978-2981	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
14-27	2982-2983	,	_
14-28	2984-2993	diffusion	_
14-29	2994-3000	tensor	_
14-30	3001-3008	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
14-31	3009-3010	(	_
14-32	3011-3014	DTI	_
14-33	3015-3016	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-34	3017-3018	,	_
14-35	3019-3021	or	_
14-36	3022-3030	positron	_
14-37	3031-3039	emission	_
14-38	3040-3050	tomography	_
14-39	3051-3052	(	_
14-40	3053-3056	PET	_
14-41	3057-3058	)	_
14-42	3059-3060	.	_

15-1	3061-3071	Additional	_
15-2	3072-3081	exclusion	_
15-3	3082-3090	criteria	_
15-4	3091-3095	were	_
15-5	3096-3097	:	_
15-6	3098-3101	not	_
15-7	3102-3104	in	_
15-8	3105-3112	English	_
15-9	3113-3114	,	_
15-10	3115-3125	substances	_
15-11	3126-3131	other	_
15-12	3132-3136	than	_
15-13	3137-3144	alcohol	_
15-14	3145-3146	,	_
15-15	3147-3165	neuropsychological	_
15-16	3166-3173	studies	_
15-17	3174-3181	without	_
15-18	3182-3194	neuroimaging	_
15-19	3195-3196	.	_

16-1	3197-3207	Extraction	_
16-2	3208-3211	and	_
16-3	3212-3219	quality	_
16-4	3220-3230	assessment	_
16-5	3231-3234	One	_
16-6	3235-3243	reviewer	_
16-7	3244-3245	(	_
16-8	3246-3248	KC	_
16-9	3249-3250	)	_
16-10	3251-3259	screened	_
16-11	3260-3269	abstracts	_
16-12	3270-3272	of	_
16-13	3273-3281	articles	_
16-14	3282-3292	identified	_
16-15	3293-3296	for	_
16-16	3297-3306	potential	_
16-17	3307-3316	relevance	_
16-18	3317-3318	.	_

17-1	3319-3323	Then	_
17-2	3324-3325	,	_
17-3	3326-3329	two	_
17-4	3330-3339	reviewers	_
17-5	3340-3341	(	_
17-6	3342-3344	AB	_
17-7	3345-3348	and	_
17-8	3349-3351	KC	_
17-9	3352-3353	)	_
17-10	3354-3367	independently	_
17-11	3368-3377	extracted	_
17-12	3378-3383	study	_
17-13	3384-3388	data	_
17-14	3389-3392	and	_
17-15	3393-3400	further	_
17-16	3401-3409	screened	_
17-17	3410-3424	bibliographies	_
17-18	3425-3427	of	_
17-19	3428-3436	relevant	_
17-20	3437-3445	articles	_
17-21	3446-3447	.	_

18-1	3448-3450	In	_
18-2	3451-3454	the	_
18-3	3455-3460	event	_
18-4	3461-3463	of	_
18-5	3464-3475	uncertainty	_
18-6	3476-3478	or	_
18-7	3479-3491	disagreement	_
18-8	3492-3501	regarding	_
18-9	3502-3510	criteria	_
18-10	3511-3514	for	_
18-11	3515-3526	eligibility	_
18-12	3527-3534	between	_
18-13	3535-3537	AB	_
18-14	3538-3541	and	_
18-15	3542-3544	KC	_
18-16	3545-3546	,	_
18-17	3547-3555	selected	_
18-18	3556-3564	articles	_
18-19	3565-3568	and	_
18-20	3569-3579	manuscript	_
18-21	3580-3585	draft	_
18-22	3586-3590	were	_
18-23	3591-3598	further	_
18-24	3599-3608	discussed	_
18-25	3609-3613	with	_
18-26	3614-3617	the	_
18-27	3618-3623	third	_
18-28	3624-3627	and	_
18-29	3628-3634	fourth	_
18-30	3635-3643	reviewer	_
18-31	3644-3645	(	_
18-32	3646-3649	FWL	_
18-33	3650-3653	and	_
18-34	3654-3656	AH	_
18-35	3657-3658	)	_
18-36	3659-3660	.	_

19-1	3661-3670	Decisions	_
19-2	3671-3673	on	_
19-3	3674-3679	study	_
19-4	3680-3689	selection	_
19-5	3690-3694	were	_
19-6	3695-3705	documented	_
19-7	3706-3708	by	_
19-8	3709-3711	AR	_
19-9	3712-3713	.	_

